Through detailed analyses on the TME of sarcomas, it may be possible to identify patients who are responsive to PD-1 therapeutic treatment by examination of expression of comprehensive bio-signatures also including PD-L1 expression, TMB, and MSI. This evidence concerns the gene PDCD1 and sarcoma.